Skip to main content
Premium Trial:

Request an Annual Quote

"Other Interests"

Billy Tauzin, president of the Pharmaceutical Research and Manufacturers of America, has resigned, effective in June, reports the Wall Street Journal. The Journal points out that Tauzin had been "taking criticism for his support of the White House's now-teetering plan to overhaul health care." Though Tauzin's departure is so that he can pursue "other interests," NPR's Shots blog notes that "it appears he may also be on the outs with some of the companies he represents in Washington" due to Tauzin's deals with Democrats on healthcare reform. Prior to joining PhRMA in January 2005, Tauzin represented Louisiana and chaired the House committee that oversaw healthcare.

The Scan

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in in human genomic research, and more.

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.